Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.8K
3.8K
RNA Splicing01:32

RNA Splicing

61.2K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.2K
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

19.2K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
19.2K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

98
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
98
Translation01:31

Translation

21.7K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
21.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estrogen Receptor-β Gene Cytosine-Adenine (<i>ESR2</i>-CA) Repeat Polymorphism in Postmenopausal Colon Cancer.

International journal of molecular sciences·2023
Same author

Rare germline variants in pancreatic cancer and multiple primary cancers: an autopsy study.

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)·2023
Same author

Sub-GOFA: A tool for Sub-Gene Ontology function analysis in clonal mosaicism using semantic (logical) similarity.

Bioinformation·2022
Same author

COL17A1 germline variant p.Ser1029Ala and mucosal malignant melanoma: An autopsy study.

Molecular and clinical oncology·2022
Same author

Trimester-specific associations between extracellular vesicle microRNAs and fetal growth.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2021
Same author

D-amino acid oxidase (DAO) rare genetic missense variant p.Pro103Leu and gastric cancer.

Molecular and clinical oncology·2021

Related Experiment Video

Updated: Mar 19, 2026

Detection of RNA-binding Proteins by In Vitro RNA Pull-down in Adipocyte Culture
10:34

Detection of RNA-binding Proteins by In Vitro RNA Pull-down in Adipocyte Culture

Published on: July 22, 2016

24.5K

Long noncoding RNA variations in cardiometabolic diseases.

Sariya Dechamethakun1, Masaaki Muramatsu1

  • 1Department of Molecular Epidemiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.

Journal of Human Genetics
|June 17, 2016
PubMed
Summary

Long noncoding RNAs (lncRNAs) are increasingly recognized for their role in cardiometabolic diseases. Understanding lncRNA variations is crucial for defining gene regulation mechanisms in these complex conditions.

More Related Videos

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.6K

Related Experiment Videos

Last Updated: Mar 19, 2026

Detection of RNA-binding Proteins by In Vitro RNA Pull-down in Adipocyte Culture
10:34

Detection of RNA-binding Proteins by In Vitro RNA Pull-down in Adipocyte Culture

Published on: July 22, 2016

24.5K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.6K

Area of Science:

  • Genetics
  • Molecular Biology
  • Cardiology

Background:

  • Cardiometabolic diseases involve multiple risk factors like diabetes, dyslipidemia, hypertension, and obesity, contributing to atherosclerosis and cardiovascular mortality.
  • Genome-wide association studies (GWASs) have identified genetic variants associated with cardiometabolic diseases, but these explain limited variability.
  • Susceptibility variants often lie in noncoding genomic regions, highlighting the importance of noncoding elements, including noncoding RNAs (ncRNAs).

Purpose of the Study:

  • To summarize recent discoveries concerning long noncoding RNA (lncRNA) variations in the context of cardiometabolic diseases.
  • To underscore the functional role of lncRNAs in cardiometabolic traits and human diseases.
  • To emphasize the need for better-defined molecular mechanisms of gene regulation by lncRNAs in cardiometabolic diseases.

Main Methods:

  • Review of recent scientific literature and genome-wide association studies (GWASs).
  • Analysis of emerging evidence on the functional roles of noncoding RNAs (ncRNAs), specifically microRNAs and long noncoding RNAs (lncRNAs).
  • Focus on genetic variations within noncoding genomic regions associated with cardiometabolic diseases.

Main Results:

  • Emerging evidence indicates that ncRNAs, including lncRNAs, play functional roles in the physiology and pathophysiology of human diseases.
  • lncRNAs are implicated in gene regulation through interactions with other molecules, influencing the development of various disorders.
  • Specific lncRNA variations are associated with cardiometabolic traits, though detailed regulatory mechanisms require further investigation.

Conclusions:

  • lncRNAs represent a significant area of research in understanding cardiometabolic diseases.
  • Further research into lncRNA variations and their molecular mechanisms is essential for advancing the field.
  • lncRNAs hold potential as therapeutic targets or biomarkers for cardiometabolic conditions.